Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells

Cellular Immunology

Volumn 249, Issue 2, 2007, Pages 63-72

  Muraro, M ^a   Mereuta, O M ^a   Carraro, F ^a   Madon, E ^a   Fagioli, F ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

Cytotoxicity; Gammadelta T cells; Osteosarcoma

Indexed keywords

CHROMIUM; INTERLEUKIN 2; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DIPHOSPHONATES; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; IMMUNOTHERAPY; OSTEOSARCOMA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS;

EID: 38949135502     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2007.11.005     Document Type: Article

References (47)

1. Bacci G., Ferrari S., Mercuri M., Bretoni F., Piccini P., Manfrini M., Gasbarrini A., Forni C., Cesari M., and Campanacci M. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop. Scand. 69 (1998) 230-236
2. Bacci G., Ferrari S., Tienghi A., Bretoni F., Mercuri M., Longhi A., Fiorentini G., Forni C., Bacchini P., Rimondini S., De Giorgi U., and Picci P. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur. J. Surg. Oncol. 27 (2001) 98-104
3. Ferrari S., Bacci G., Picci P., Mercuri M., Briccoli A., Pinto D., Gasbarrini A., Tienghi A., and Brach del Prever A. Long term follow-up and post-relapse survival in patients with nonmetastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann. Oncol. 8 (1997) 765-771
4. Fagioli F., Aglietta M., Tienghi A., Ferrari S., Brach del Prever A., Vassallo E., Palmero A., Biasin E., Bacci G., Picci P., and Madon E. High dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian Sarcoma Group study. J. Clin. Oncol. 20 (2002) 2150-2156
5. Sudo T., Kuramoto T., Komiya S., Inoue A., and Itoh K. Expression of MAGE genes in osteosarcoma. J. Orthop. Res. 15 (1997) 128-132
6. Naka N., Araki N., Nakanishi H., Itoh K., Mano M., Ishiquro S., de Bruijn DR., Myoui A., Ueda T., and Yoshikawa H. Expression of SSX genes in human osteosarcomas. Int. J. Cancer 98 (2002) 640-642
7. Tsuda N., Murayama K., Ishida H., Matsunaga K., Komiya S., Itoh K., and Yamada A. Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J. Orthop. Res. 19 (2001) 346-351
8. Chirgwin J.M., and Guise T.A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit. Rev. Eukaryot. Gene Expr. 10 (2000) 159-178
9. Body J. Clinical research update: zoledronate. Cancer 80 (1997) 1699-1701
10. Cheer S., and Noble S. Zoledronic acid. Drugs 61 (2001) 799-805
11. Gatti D., and Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 15 (1999) 285-296
12. Pataki A., Muller K., Green J., Ma Y., Li Q., and Jee W. Effects of short term treatment with the bisphosphonate zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat. Rec. 249 (1997) 458-468
13. Benford H.L., McGowan N.W.A., Helfrich M.H., Nuttall M., and Rogers M.J. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28 (2001) 465-473
14. Berenson J., Rosen L., Howell A., Porter L., Coleman RE., Morley W., Dreicer R., Kuross SA., Lipton A., and Seaman JJ. Zoledronic acid reduces skeletal-related events in patients with osteolytic lesions. Cancer 91 (2001) 1191-1200
15. Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer 88 (2000) 3033-3037
16. Corey E., Brown L.G., Quinn J.E., Poot M., Roudier M.P., Higano C.S., and Vessella R.L. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin. Cancer Res. 9 (2003) 295-306
17. Lee Y.P., Schwarz E.M., Davies M., Jo M., Gates J., Zhang X., Wu J., and Lieberman J.R. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res. 62 (2002) 5564-5570
18. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart JM., Castronovo V., and Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302 (2002) 1055-1061
19. Anderson KC., Kyle RA., Dalton WSm., Landowski T., Shain K., Jove R., Hazlehurst L., and Berenson J. Multiple myeloma: new insights and therapeutic approaches. Hematol. Am. Soc. Hematol. Educ. Program. 1 (2000) 147-165
20. Saad F., Gleason DM., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin JL., Vinholes JJ., Goas JA., and Chen B. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Natl. Cancer Inst. 94 (2000) 1458-1468
21. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., Pawlicki M., de Souza P., Zheng M., Urbanowitz G., Reitsma D., and Seaman J.J. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial, The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21 (2003) 3150-3157
22. Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F.H., Delmas P.D., and Clézardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57 (1997) 3890-3894
23. Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., Delmas P., Delaissé J.M., and Clézardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60 (2000) 2949-2954
24. Smyth M.J., Godfrey D.I., and Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2 (2001) 293-299
25. Kelly J.M., Darcy P.K., Markby J.L., Godfrey D.I., Takeda K., Yagita H., and Smith M.J. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3 (2002) 83-90
26. Parker C.M., Groh V., Band H., Porcelli S.A., Morita C., Fabbi M., Glass D., Strominger J.L., and Brenner M.B. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J. Exp. Med. 171 (1990) 1597-1612
27. Tanaka Y. Human γδ T cells and tumor immunotherapy. J. Clin. Exp. Hematopathol 46 (2006) 11-23
28. Bukowski J.F., Morita C.T., and Brenner M.B. Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 11 (1999) 57-65
29. Mariani S., Muraro M., Pantaleoni F., Fiore F., Nuschak B., Peola S., Foglietta M., Palumbo A., Coscia M., Castella B., Bruno B., Bertieri R., Boano L., Boccadoro M., and Massaia M. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19 (2005) 664-670
30. Selin L.K., Steward S., Shen C., Mao H.Q., and Wilkins J.A. Reactivity of gamma delta T cells induced by the tumor cell line RPMI 8226: functional heterogeneity of clonal populations and role of GroEL heat shock proteins. Scand. J. Immunol. 36 (1992) 107-117
31. Schultze J.L., and Nadler L.M. T cell mediated immunotherapy for B cell lymphoma. J. Mol. Med. 77 (1999) 322-331
32. Bubenik J. Tumour MHC class I down regulation and immunotherapy. Oncol. Rep. 10 (2003) 2005-2008
33. Kunzmann V., Bauer E., Feurle J., Weissinger F., Tony H.P., and Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of anti-plasma cell activity in multiple myeloma. Blood 96 (2000) 384-392
34. Sicard H., Al Saati T., Delsol G., and Fournié J.J. Synthetic phosphoantigens enhance human Vγ9Vδ2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol. Med. 7 (2001) 711-722
35. Kato Y., Tanaka Y., Tanaka H., Yamashita S., and Minato N. Requirement of species-specific interactions for the activation of human gamma delta T cells by pamidronate. J. Immunol. 170 (2003) 3608-3613
36. Kato Y., Yoshimasa T., Fumi M., Seiji Y., and Nagahiro M. Targeting of tumor cells for human γδ T cells by nonpeptide antigens. J. Immunol. 167 (2001) 5092-5098
37. Kabelitz D., Wesch D., Pitters E., and Zoller M. Potential of human γδ T lymphocytes for immunotherapy of cancer. Int. J. Cancer 12 (2004) 727-732
38. Miyagawa F., Tanaka Y., Yamashita S., and Minato N. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γδ T cells by aminobisphosphonate antigen. J. Immunol. 166 (2001) 5508-5514
39. Dieli F., Gebbia N., Poccia F., Caccamo N., Montesano C., Fulfaro F., Arcara C., Valerio M.R., Meraviglia S., Di Sano C., Sireci G., and Salerno A. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102 (2003) 2310-2311
40. Stresing V., Daubiné F., Benzaid I., Monkkonen H., and Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett. 257 (2007) 16-35
41. Gober H.J., Kistowska M., Angman L., Jeno P., Mori L., and De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197 (2003) 163-168
42. Wilhelm M., Kunzmann V., Eckstein S., Reimer P., Weissinger F., Ruediger T., and Tony H.P. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 102 (2003) 200-206
43. Morita C.T., Mariuzza R.A., and Brenner M.B. Antigen recognition by human γδ T cells: pattern recognition by the adaptive immune system. Springer Semin. Immunopathol. 22 (2000) 191-217
44. Bendelac A., and Bonneville M. Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol. 1 (2001) 177-185
45. Girardi M., Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., Hobby P., Sutton B., Tigelaar R.E., and Hayday A.C. Regulation of cutaneous malignancy by γδ T cells. Science 294 (2001) 605-609
46. de Vries E., van der Weij J.P., van der Veen C.J., van Paassen H.C., Jager M.J., Sleeboom H.P., Bijvoet O.L., and Cats A. In vitro effect of (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation. Immunology 47 (1982) 157-163
47. Tanaka Y., Kobayashi H., Terasaki T., Toma H., Aruga A., Uchiyama T., Mizutani K., Mikami B., Morita C.T., and Minato N. Synthesis of pyrophosphate-containing compounds that stimulate Vγ2δ2 T cells: application to cancer immunotherapy. Med. Chem. 3 (2007) 85-99